Medical Marijuana, Inc. Portfolio Investment Company, Kannalife Sciences, Inc. Receives Publication Through American Chemical Society for KLS-13019, a Novel Cannabidiol-Derived Target Drug Candidate for Hepatic Encephalopathy
SAN DIEGO, 2016-02-18 15:00 CET (GLOBE NEWSWIRE) --
Medical Marijuana, Inc. (OTC Pink:MJNA) is pleased to announce that the Company’s portfolio investment company, Kannalife Sciences, Inc. (“Kannalife”), has made a major breakthrough in the field for cannabinoid therapeutics with the publication of the body of science behind the new cannabidiol (CBD)-like molecule KLS-13019. The abstract, as well as the purchase of the full version of the publication on the “Discovery of KLS-13019” is available online at:http://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.6b00009.
“We are very excited to see the progress being made at Kannalife toward their pharmaceutical development of cannabinoid-derived therapeutic agents,” states Dr. Stuart W. Titus, Chief Executive Officer of Medical Marijuana, Inc. “With the development of KLS-13019, there is potential for orphan drug designation in Grade 3 hepatic encephalopathy (HE). Pre-clinical studies have led Kannalife’s scientific team to believe KLS-13019 may successfully provide answers for late-stage HE patients.”
Through pre-clinical testing and pharmacokinetic (PK) studies, Kannalife’s findings indicate improvement over CBD’s role as a neuroprotectant in both increased potency and reduction of toxicity. Side-by-side comparisons between CBD and KLS-13019 have also shown that KLS-13019 has marked improvements over CBD in oral bioavailability, CNS penetration, blood-plasma concentrations, and cognitive improvement in pilot murine behavioral models. The published findings explain that KLS-13019 was 50-fold more potent and >400-fold safer than cannabidiol (CBD) and exhibited an improved in vitro profile consistent with improved oral bioavailability.
Titus continues, “The potential for KLS-13019 and its significance stands beyond its intended target of ameliorating neurodegeneration brought on by ethanol and ammonium toxicity but also its potential in repairing liver damage brought on by cirrhosis. A successful clinical trial may also lead to other important areas such as the use of KLS-13019 as a possible adjuvant as a long-term solution for drug-induced liver disease.”
Drug-induced liver toxicity (DILI) is a common cause of liver injury. It accounts for approximately one-half of the cases of acute liver failure and mimics all forms of acute and chronic liver disease. An estimated 1,000 drugs have been implicated in causing liver disease on greater than one occasion. Although, with the exception of rare cases, drug-induced liver injury subsides after cessation of treatment with the drug, this represents an important diagnostic and therapeutic challenge for physicians.
About Kannalife Sciences, Inc.
Kannalife Sciences, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy ("HE") and Chronic Traumatic Encephalopathy ("CTE"). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions. For more information, visit: www.Kannalife.com.
About Medical Marijuana Inc.
The mission of Medical Marijuana, Inc. (OTC Pink:MJNA) is to be the premier cannabis and hemp industry innovator, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For more information, please visit the company's website at:
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
For further information, please contact:
Public Relations contact:
Chief Executive Officer
Medical Marijuana, Inc.
Toll Free: 888-OTC-MJNA (888-682-6562)
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Nitinat Provides Update on the Carscallen Gold Property19.3.2018 21:30 | Pressemelding
TORONTO, March 19, 2018 (GLOBE NEWSWIRE) -- Further to its press release dated March 12, 2018 whereby Nitinat Minerals Corp. (the "Corporation") (TSX-V:NZZ) (Frankfurt:04U1) announced its option to acquire four (4) additional claims (collectively, the "Claims") abutting the western boundaries of the Corporation's current mining claims in Carscallen Township, Ontario (the "Carscallen Gold Property"), the Corporation is pleased to provide additional information pertaining to the Claims. The Corporation intends to implement an exploration program for the Claims to fully explore the potential of the Claims. The "preliminary technical appraisal" provided herein, along with the geophysics that the Corporation intends to undertake, will identify potential drill targets. The property encompassing the Claims is of particular interest in that surface exploration to date on the Claims has shown the existence of historic surface mining and sampling. The Corporation is currently assessing the most
New Elemica Trace Solution Delivers Shipment Risk Analysis for Digital Transformation19.3.2018 13:09 | Pressemelding
Real-Time Information Matched with GPS Locations Provides Accurate Delivery Information WAYNE, Pa., March 19, 2018 (GLOBE NEWSWIRE) -- Elemica, the leading Digital Supply Network for process manufacturing industries, introduces Elemica Trace, a solution that provides real-time shipment and risk visibility to customer service, transport planners, and supply chain managers, allowing them to monitor and proactively manage the movement of products to customers and inbound to manufacturing centers. "Shipment disruptions occur and teams can spend hours manually tracking down what is happening. What's worse, sometimes your customer complaint is the first indication you have of a late shipment," said Rich Katz, CTO of Elemica. "Trace eliminates the time and stress of tracking shipments and enables your teams to increase the positive interactions with your customers." Elemica Trace uses shipment data, carrier signals, a geo-location interface, and predictive algorithms to identify shipments in
Resverlogix Exceeds Full Enrollment for the Pivotal Phase 3 BETonMACE Clinical Trial19.3.2018 12:00 | Pressemelding
The BETonMACE trial has now surpassed 2,400 enrolled patients and topline data is expected around the end of 2018 CALGARY, Alberta, March 19, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has successfully surpassed the planned enrollment target of over 2,400 patients in the ongoing Phase 3 BETonMACE trial. The trial's first patient was enrolled on November 11th, 2015. The goal of the trial is to confirm the effect of Resverlogix' lead drug, apabetalone, in Cardiovascular Disease (CVD) patients with type 2 Diabetes Mellitus (DM) and low high-density lipoproteins (HDL). The primary endpoint of the BETonMACE trial is designed to establish a relative risk reduction (RRR) of Major Adverse Cardiac Events (MACE), narrowly defined as a single composite endpoint of cardiovascular death, non-fatal myocardial infarction (MI) and stroke. Secondary pre-specified endpoints in the trial will also examine renal function and MACE in patien
SolarWinds Places Highest on the Ability to Execute Axis in 2018 Gartner Magic Quadrant for Network Performance Monitoring and Diagnostics19.3.2018 11:30 | Pressemelding
AUSTIN, Texas, March 19, 2018 (GLOBE NEWSWIRE) -- SolarWinds, a leading provider of powerful and affordable IT management software, placed highest on the ability to execute axis in the 2018 Gartner Magic Quadrant for Network Performance Monitoring and Diagnostics1. This Gartner report evaluated 22 suppliers of Network Performance Monitoring and Diagnostics products. The firm's evaluation criteria for ability to execute included the following: product or service, overall viability, sales execution and pricing, market responsiveness and record, marketing execution, customer experience, and operations. Of all the vendors evaluated in the report, SolarWinds placed highest on the ability to execute axis. "For three years in a row, Gartner has positioned us as highest on the ability to execute axis in the Magic Quadrant for Network Performance Monitoring and Diagnostics. In our view, this result confirms our commitment to helping our customers manage their network operations with a powerful
Record High Number of Toll Transactions Cleared in Ireland in 201719.3.2018 10:51 | Pressemelding
ISSY LES MOULINEAUX, France, March 19, 2018 (GLOBE NEWSWIRE) -- The number of transactions processed through emovis's toll interoperability cloud-based hub in Ireland has reached a record high with over 50 million transactions cleared in 2017. Thanks to its toll interoperability solution, emovis is contributing to the improved mobility of millions of Irish drivers, by allowing them to travel seamlessly with just one toll tag across the whole country. As of January 2018, over 650,000 toll transponders are in use. With this new success, emovis demonstrates its leadership in designing and operating innovative mobility solutions that offer the best levels of service for road users in Ireland and throughout the world. About eToll.ie emovis was awarded the contract for managing Ireland's toll interoperability hub by the National Roads Authority (now Transport Infrastructure Ireland) in June 2013 following a competitive tender. As part of this contract, emovis designed, developed and is curre
Phenom People Set to Attend UNLEASH London19.3.2018 09:00 | Pressemelding
Candidate Experience Software Pioneer Attends UK Conference HORSHAM, Pa., March 19, 2018 (GLOBE NEWSWIRE) -- Phenom People, the leader in Talent Relationship Marketing (TRM), announced today that it will attend UNLEASH Conference & Expo on March 20-21 at the ExCel London. "We are no stranger to UNLEASH's strong turnout of highly passionate and forward-thinking individuals who are ready for the next big thing in technology. The inspiration and exchange of new ideas from the world's greatest thought leaders UNLEASH draws in every year, is what we look forward to the most," said Mahe Bayireddi CEO at Phenom People. "Our presence at this year's UNLEASH is vitally important as we continue to emerge as a global TRM leader with a growing list of European clients." UNLEASH, formerly HR Tech World, is held around the globe and was created to enhance the Future of Work by marrying technology with efficient business practices. UNLEASH London's speaker line-up consists of many big-league names inc
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom